New artificial intelligence technology is helping diagnose the U.S.’s most deadly cancer sooner, greatly improving the ...

About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...

Breaking barriers for patients with stage IV non-small cell lung cancer with brain metastases: Insight into the impact of immunotherapy on survival and survival disparities. This is an ASCO Meeting ...

Stereotactic ablative radiotherapy (SABR) offers patients with early-stage non-small cell lung cancer (NSCLC) an effective alternative to the standard of care surgery — with significantly fewer severe ...

Lung Cancer Canada (LCC) and Boehringer Ingelheim Canada (Boehringer) are pleased to announce a new collaboration aimed at reimagining detection and accelerating innovation in non-small cell lung ...

Ask a clinical question and tap into Healio AI's knowledge base. Lung cancer is generally the top cause of cancer-related death globally and in the United States (US). In the US in 2023, lung cancer ...

Lung cancer remains the most frequently diagnosed malignancy and the leading cause of cancer tumour-related mortality ...

Please provide your email address to receive an email when new articles are posted on . “We believe that these results are quite powerful and informative,” Christopher Seder, MD, thoracic surgeon at ...

Imdelltra significantly improves survival in SCLC patients post-platinum chemotherapy, meeting primary endpoints in the DeLLphi-304 trial. As a BiTE immunotherapy, Imdelltra enhances T cell-cancer ...

Imdelltra significantly improved progression-free and overall survival compared to chemotherapy in small cell lung cancer patients, with a median overall survival of 13.6 months versus 8.3 months. The ...

Future SCLC treatment may involve combining T-cell engagers with immune checkpoint inhibitors to enhance patient outcomes.